China-based cancer screening service provider Creative Biosciences has secured $87m in a series D round led by e-commerce group Alibaba, DealStreetAsia reported on Friday.
Financial services firm Agriculture Bank of China’s ABC International subsidiary also took part in the round, alongside Huaxing Growth Capital, Costone Capital, Henglu Asset and IDG Capital.
Creative Biosciences provides early-stage cancer screening diagnostic kits for a range of cancers including lung, liver, bladder, cervix and colorectal.
The company raised $88m in a September 2020 series C round led by Tsing Song Capital that also featured Oceanpine Capital, GDD Industry Fund Investment Group, Judu Investment, Sharewin Capital, Linden Asset, Guangzhou Jinkong Fund, IDG Capital, Think Real and CDH Investments.
The 2020 round came after Creative received $44.7m in a 2019 series B round co-led by IDG Capital and CDH Investments that included two funds affiliated with medical testing services provider Kingmed Diagnostics in addition to CD Capital.
Kingmed and CD Capital had also invested in the company’s $9m series A round in 2017, following $2.2m in pre-series A funding from pharmaceutical firm Tasly’s corporate venturing arm, Tasly Capital, in 2016. Sungent BioVenture had provided it with $3m in angel funding the previous year.
